Xenetic Biosciences, Inc. (XBIO) Investor Relations Documents

Xenetic Biosciences, Inc. (XBIO) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2026-06-03. Read in-app with summaries. First-party data.

XBIO_June+Investor+Presentation_June+2026.pdf: Xenetic Biosciences is advancing its DNase I technology platform to target Neutrophil Extracellular Traps (NETs) for multiple cancer indications, with a planned Phase 1 study for

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releaseXenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supp
2026-08-07Press releaseXenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supp
2026-06-04Press releaseXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health
2026-06-03PresentationXBIO_June+Investor+Presentation_June+2026.pdf
2026-06-01Press releaseXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persiste
2026-06-01Press releaseXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persiste
2026-05-13Press releaseXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology
2026-05-13Press releasePDF
2026-04-22Press releaseXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
2026-03-13Press releaseXenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

XBIO overview · XBIO earnings · XBIO financials · XBIO KPIs · XBIO ownership · XBIO peers · XBIO filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.